These treatments eliminate cancer cells by inducing DNA damage, a common anticancer strategy 18,19
The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
A key data point for researchers is the "responder rate." In the retatrutide Phase 2 trial, 100% of the participants in the 8 mg and 12 mg dose groups achieved a weight reduction of at least 5%
Legality varies by jurisdiction
34-amino-acid research analog
Cardiovascular medications: Caution with statins, digoxin, or warfarin